Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionMhairi Copland(Blood Cancer UK), Tessa L. Holyoake(Gartnavel General Hospital)BloodFebruary 10, 200610.1182/blood-2005-07-2947Cited by 632SaveCiteExport RISWatch citationsRelated PapersAdult hematopoietic stem cells lacking Hif-1α self-renew normally|Blood|2016|80CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells|Blood|2016|70